Business Wire

MI-EATON

24.5.2022 12:32:14 CEST | Business Wire | Press release

Share
Eaton’s eMobility Business Introduces Battery Disconnect Unit Featuring Updated Breaktor® Circuit Protection Technology

Power management company Eaton today announced its eMobility business has introduced a battery disconnect unit (BDU) that can be combined with upgraded Breaktor® circuit protection technology to provide circuit protection in electrified vehicles (EVs) while reducing overall complexity and cost.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005297/en/

When paired with the Breaktor circuit protection technology, which combines current switching and resettable bidirectional short-circuit protection with fast actuation, Eaton’s BDU eliminates the need for up to 15 additional system components. Traditional systems require a combination of pyro and thermal fuses and contactors.

“As manufacturers continue to increase the power levels in EVs, it’s increasingly important to have capable and dependable protection solutions,” said Kevin Calzada, global product strategy manager, Eaton’s eMobility business. “Our BDU combined with our Breaktor circuit protection technology provides everything needed, in a compact and efficient package, to protect the vehicle and occupants.”

The BDU’s primary function is to serve as an on/off switch to the battery depending on the mode the EV is operating in, such as charging or driving. Current model EVs rely on one of three traditional BDU configurations: fuse and contactor; pyro fuse and contactor; or fuse, pyro fuse and contactor, all used together in a single BDU. While all provide switching and protection functions, they each have disadvantages, including overall system complexity, serviceability, coordination difficulties and susceptibility to fatigue under high current levels.

Adding Breaktor circuit protection technology to Eaton’s BDU provides extra functionality and benefits, including active and passive actuation in a single device; the capability to transition to an off-state under a wide range of fault conditions; improved functional safety; the ability to be reset after a high-energy fault; and the ability to replace up to four high-voltage electrical components, which reduces complexity and system-level cost.

“Our Breaktor circuit protection technology’s self-triggering design, diagnostic electronics and mirror contact help achieve BDU functional safety goals,” Calzada said. “With its integrated coil driver, economizer, and the sensing/triggering circuit, Breaktor circuit protection technology also reduces battery management-system cost and complexity.”

Eaton’s Breaktor circuit protection technology also enables up to 350 kW DC fast charging when used to protect and switch the DC fast-charge circuit, allowing EVs to charge in 15 minutes or less. This capability is made possible by recent upgrades to the Breaktor circuit protection technology’s thermal management and materials to boost its power capacity. Breaktor circuit protection technology is now able to carry 500 amps continuously and up to 750 amps of continuous current when an active or passive cooling system is leveraged.

“Breaktor achieves best-in-class current ratings, and these can be even further increased with an appropriate cooling strategy,” Calzada said. “Eaton is able to design and develop a compatible cooling system to customer specifications and integrated into a BDU to meet these rising power requirements.”

Learn more about Eaton’s battery disconnect unit.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com . Follow us on Twitter and LinkedIn.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye